Norgine is committed to the prevention of colorectal cancer

Back to media releases
Next media release
05 March 2018

 

CORPORATE MEDIA RELEASE

NORGINE IS COMMITTED TO THE PREVENTION OF COLORECTAL CANCER

AMSTERDAM. The Netherlands, Monday 5 March 2018, 08:00 AM CET. Norgine B.V. today announced its continued support to the European Colorectal Cancer awareness campaign throughout the month of March 2018 #Time4Change, #ECCAM18.

Norgine is a market leader in providing bowel cleansing and colonoscopy products which aim to facilitate high quality colonoscopy. Colonoscopy is a vital screening procedure to detect and remove adenomas and polyps that can result in colorectal cancer. Colorectal cancer is the second most common cause of cancer-related mortality in Europe, with over 447,000 new diagnoses every year.[i] Colorectal cancer is largely preventable, with early detection being associated with a 90% cure rate.[ii]  

Norgine’s bowel cleansing and colonoscopy portfolio includes KLEAN-PREP®, MOVIPREP®, ENDOCUFF VISION® and PLENVU®. http://www.expertiseincolonoscopy.com/

As a leader in colonoscopy, Norgine has been collaborating with key European patient organisations in order to increase the detection of colorectal cancer and to help improve patients’ quality of life. Click here to view the full list of all organisations to whom Norgine provides support.

 

ends

Notes to Editors:

About Norgine

Norgine is a leading European specialist pharmaceutical company with a direct commercial presence in all major European markets. In 2017, Norgine’s total net sales were EUR 345 million, up 17 per cent.

Norgine employs over 1,000 people across its commercial, development and manufacturing operations and manages all aspects of product development, production, marketing, sale and supply.

Norgine specialises in gastroenterology, hepatology, cancer and supportive care.

Norgine is headquartered in the Netherlands. Norgine owns a R&D site in Hengoed, Wales and two manufacturing sites in Hengoed, Wales and Dreux, France.

For more information, please visit www.norgine.com

In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com.

NORGINE and the sail logo are trademarks of the Norgine group of companies.

 

Media Contact:

Isabelle Jouin, T: +44 (0)1895 826237

Follow us @norgine

GL/COR/0318/0132

 

[i] Epidemiology of colorectal cancer in Europe. Source: GLOBOCAN 2012

[ii] Bowel Cancer UK. Available at https://www.bowelcanceruk.org.uk/about-bowel-cancer/screening/. Accessed on 2 March 2018